Skip to main content

Table 1 Baseline characteristics of patients with metastatic colorectal cancer (mCRC) who were treated with famitinib or placebo in the full analysis set

From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Characteristic

Whole cohort

Famitinib group

Placebo group

P value

Total (cases)

154

99

55

 

Age (years)

0.352

 Mean ± SD

54.1 ± 9.5

54.7 ± 9.9

53.2 ± 8.8

 

 Median (range)

55 (24–71)

55 (24–70)

54 (32–71)

 

Age group [cases (%)]

0.437

 > 60 years

106 (68.8)

66 (66.7)

40 (72.7)

 

 ≤ 60 years

48 (31.2)

33 (33.3)

15 (27.3)

 

Gender [cases (%)]

0.679

 Male

89 (57.8)

56 (56.6)

33 (60.0)

 

 Female

65 (42.2)

43 (43.4)

22 (40.0)

 

ECOG performance status [cases (%)]

0.776

 0

27 (17.5)

18 (18.2)

9 (16.4)

 

 1

127 (82.5)

81 (81.8)

46 (83.6)

 

LDH level [cases (%)]

0.663

 ≤ 1.5 × ULN

126 (81.8)

80 (80.8)

46 (83.6)

 

 > 1.5 × ULN

28 (18.2)

19 (19.2)

9 (16.4)

 

Number of metastatic organs [cases (%)]

0.499

 ≤ 2

84 (54.5)

56 (56.6)

28 (50.9)

 

 > 2

70 (45.5)

43 (43.4)

27 (49.1)

 

Primary site of disease [cases (%)]

0.485

 Rectum

73 (47.4)

49 (49.5)

24 (43.6)

 

 Colon

81 (52.6)

50 (50.5)

31 (56.4)

 

History of primary tumor resection [cases (%)]

0.559

 No

14 (9.1)

10 (10.1)

4 (7.3)

 

 Yes

140 (90.9)

89 (89.9)

51 (92.7)

 

History of anti-tumor monoclonal antibody therapy [cases (%)]

0.579

 No

83 (53.9)

55 (55.6)

28 (50.9)

 

 Yes

71 (46.1)

44 (44.4)

27 (49.1)

 

Famitinib treatment as [cases (%)]

0.622

 Third-line therapy

60 (39.0)

40 (40.4)

20 (36.4)

 

 > Third-line therapy

94 (61.0)

59 (59.6)

35 (63.6)

 

White blood cell count (109/L)

0.646

 Mean ± SD

6.6 ± 2.5

6.7 ± 2.4

6.5 ± 2.7

 

 Median (range)

6.1 (3.0–17.0)

6.2 (3.0–15.0)

5.8 (3.0–17.0)

 

Alkaline phosphatase (U/L)

0.887

 Mean ± SD

127.3 ± 82.8

126.6 ± 82.6

128.6 ± 84.0

 

 Median (range)

104.0 (26.0–580.0)

105.0 (26.0–580.0)

103.0 (46.0–458.0)

 
  1. SD standard deviation, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, ULN upper limit of normal